RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies
This study has been completed.
Information provided by:
Reata Pharmaceuticals, Inc.
First received: September 12, 2007
Last updated: December 19, 2008
Last verified: December 2008
This study assesses the tolerability, safety, efficacy and pharmacokinetics of RTA 402 in advanced solid tumors and lymphoid malignancies.
Advanced Solid Tumors
Drug: RTA 402
||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||A Phase I Dose-Finding and Pharmacokinetic Study of RTA 402 (CDDOMe) Administered Orally for 21 Days of a 28-Day Cycle in Patients With Advanced Solid Tumors or Lymphoid Malignancies
Primary Outcome Measures:
- To determine the dose-limiting toxicity, maximum tolerated dose, and recommended phase II dose of RTA 402 Capsules
- To characterize the pharmacokinetics of RTA 402 in this patient population.
Secondary Outcome Measures:
- To document any preliminary antitumor activity.
- To determine the in vivo molecular and biological effects.
- To correlate the biological activity of RTA 402 with drug concentration in plasma and blood cellular elements.
| Study Start Date:
RTA 402 is a synthetic triterpenoid that has demonstrated significant in vivo single agent anti-cancer activity. This is an open-label phase I dose-escalation study of RTA 402 administered orally for the first 21 days of a 28-day cycle.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Histopathological documentation of solid tumor or lymphoid malignancy.
- Advanced or metastatic cancer that is either refractory to or have relapsed after standard-of-care curative or survival-prolonging therapy, or for whom no such therapies exist.
- ECOG performance status of less than or equal to 2
- Adequate liver and renal function as documented by the following laboratory test results within 14 days of starting therapy: total bilirubin ≤ 1.5 mg/dL; AST (SGOT) and ALT(SGPT) ≤ 2.5 ULN or ≤ 5 ULN if liver is involved by tumor; serum creatinine ≤2.0 mg/dL OR creatinine clearance >60 mL/min.
- Adequate bone marrow function as documented by the following laboratory test results within 14 days of starting therapy: platelets greater than 100,000/mm3, absolute granulocyte count greater than 1,500/mm3, hemoglobin greater than or equal to 8.0 g/dl.
- Completion of prior chemotherapy, hormonal therapy, radiation therapy, biological therapy, or other investigational cancer therapy, for at least 4 weeks prior to study entry and must have recovered from all acute side effects (to CTC grade 1 or less) prior to initiation of RTA 402. Patients who were receiving mitomycin C or nitrosoureas must be 6 weeks from the last administration of chemotherapy.
- Agree to practice effective contraception during the entire study period.
- Life expectancy of more than 3 months
- Able and willing to sign the informed consent form.
- Willing and able to self-administer orally and document all doses of RTA 402 ingested.
- Active brain metastases or primary CNS malignancies.
- Pregnant or breast feeding
- Clinically significant illnesses including, but not limited to: Uncontrolled diabetes; Active or uncontrolled infection; Acute or chronic liver disease; Confirmed diagnosis of HIV infection; Uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, or uncontrolled cardiac arrhythmia.
- Psychiatric illness that would limit compliance with study requirements.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00529438
|Beth Israel Deaconess Medical Center
|Boston, Massachusetts, United States, 02215 |
|Case Western Reserve University
|Cleveland, Ohio, United States, 44106 |
|MD Anderson Cancer Center
|Houston, Texas, United States, 77030 |
Reata Pharmaceuticals, Inc.
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||September 12, 2007
||December 19, 2008
||United States: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on December 11, 2013